• Cuello Juan Pablo JP Servicio de Neurología, Hospital General Universitario Gregorio Marañón, Madrid, España. Electronic address: juancuelloneuro@gmail.com., Paula Salgado Cámara, José Manuel García Domínguez, Alberto Lozano Ros, Miguel Mas Serrano, and María Luisa Martínez Ginés.
• Servicio de Neurología, Hospital General Universitario Gregorio Marañón, Madrid, España. Electronic address: juancuelloneuro@gmail.com.
• Med Clin (Barc). 2020 Mar 27; 154 (6): 214-217.

IntroductionIn multiple sclerosis (MS), foetal exposure to disease-modifying drugs (DMDs) carries varying degrees of risk. We sought to analyse the clinical and obstetric outcomes of MS patients (MSp) exposed to DMDs during pregnancy.Patients And MethodsObservational study. We analysed the clinical-obstetric data of a cohort MSp, who became pregnant between 2007-2017. They were prospectively followed up during pregnancy and postpartum.Control Grouphealthy pregnant women (HPW) and MSp unexposed to DMDs.ResultsSixty-eight pregnancies in MSp. Fifty-six HPW. Thirteen MSp were exposed to DMDs during pregnancy. Obstetric outcome: 2 (15%) infants had low birth weight, no preterm deliveries. Fifty-five MSp were not exposed to DMDs: 22 (40%) discontinued DMD before pregnancy, 33(60%) naïve. Five infants (9%) had low birth weight and 7 (12%) were preterm. HPW: 56. Low birth weight 6 (11%), preterm delivery 6 (11%). There were no differences in relapse incidence during pregnancy-puerperium between MSp groups. There were no differences in birth weight, gestation time, delivery-caesarean section. We found no special obstetric morbidity in women exposed to DMDs.ConclusionsThere were no significant differences in the clinical and obstetric variables analysed between pregnant women exposed to DMDs, unexposed, and HPW.Copyright © 2019 Elsevier España, S.L.U. All rights reserved.

8 keywords...

hide…